Archive

Medicine

FDA has been cultivating partners in the drug industry, too. Their new goal is to "make safe and effective drugs available" to Americans, whether from the most conventional processes or from the newest biotechnology. FDA will never compromise on safety, but that is not stopping them from cutting out bureaucracy. Scios, Inc., a northern California pharmaceutical manufacturer, recently wrote the agency thanking it for its new approach, in which inspectors work with companies to identify and correct problems, rather than just issue reports of deviations.(5) Citing a recent visit to its facility by an FDA inspector, a company vice president remarked on the frustrating history of industry relations with the agency, noting that, "... since the late 1980s, relations between FDA and its regulated industries have been on a steady and disheartening decline." However, the new approach taken by the FDA inspection team was a refreshing change: "Our goal is to get safe and effective therapies on the market as soon as possible; you've contributed to this effort," the executive states in commenting on the new and welcome change in the FDA.

FDA has been working in partnership with industry researchers to create safe, effective new drugs against cancer and other killers, and to market them fast. For example, they worked with Merck & Co., Inc., to make an important new tool in the fight against HIV/AIDS available faster. Knowing that scientists at Merck were nearing a breakthrough on a new drug to treat HIV/AIDS, the FDA set up advance teams for regulatory review and manufacturing inspection to reduce delays in the approval process. In particular, the Baltimore district office of FDA worked with Merck's Elkton, Virginia, facility to integrate the review process with the construction of the new manufacturing plant and validation of the manufacturing process. As a result, Crixivan, one of a new class of protease inhibitors offering significant new treatment in the fight against HIV/AIDS, was cleared for the market in 42 days, the fastest ever approval of a new drug by the FDA.

CONTENTS
Navigation Bar For NPR site Back To The NPR Main Page Search the NPR Site NPR Initiatives Links to Other Reinvention Web Sites Reinvention Tools Frequently Asked Questions NPR Speeches NPR News Releases